#ocrelizumab

[u2hearts]

My age 51 my body is much older

My age 51 my body is much older

It’s my birthday tomorrow. 51!!! I’m middle age. I think my body has been middle age since I was 43. That was when multiple sclerosis hit me with the last relapse that started my path of true disability. It’s been 8 years since that last relapse. It was when I was switching from Tysabri to Rituxan. I made the mistake of stopping Tysabri because I actually had the thought of switching to an…

[joseywritesng]

How does B cell therapy for multiple sclerosis work?

How does B cell therapy for multiple sclerosis work?

After Cherie Binn’s breakthrough symptoms of multiple sclerosis developed while being treated with an interferon drug, she weighed her options carefully. Finally, her neurologist prescribed rituximab. It’s a type of B cell therapy, which gets its name because it targets the B cells that cause nerve damage when you have MS. Binns, a 69-year-old nurse who works with MS patients in Wakefield, RI,…

[limbic-system-failure]

domenica mia madre mi ha chiamata.

dopo il solito small talk, con esitazione e paura, mi ha sussurrato: "lo sai che è uscita una nuova terapia?"

No mamma, non lo so, ma c'è stato Ectrims due giorni fa, ne hanno parlato al TG?

sì

E cos'hanno detto?

che questo farmaco nuovo ferma la malattia per sempre, le persone che lo prendono è come se non la avessero

(ma io come faccio a dirti che non guarisco mai? l'unica cosa che posso dirti è) Ah, davvero? Sai come si chiama?

sì sì l'ho segnato, aspetta, si chiama... ocrelizumab

Mà l'ocrelizumab è vecchio di anni, non è un nuovo farmaco.

sì ma hanno detto che... hanno usato un termine specifico... arresta? no... blocca le... no... poi ti mando un link, ma tu come mai non lo fai?

Perché per ora vediamo come va con il Mavenclad, mà.

vabbè ma hanno detto che è come se la malattia non esistesse più!

(ma io come te lo dico, come te lo dico, mamma scusami, non l'ho fatto di proposito ad ammalarmi, scusa vado al sole quante volte vuoi, scusa tornassi indietro se potessi non mi ammalerei, ti chiedo scusa) Sì, conosco molte persone che lo stanno facendo e stanno alla grande, per fortuna. Peccato per gli effetti collaterali.

ah, sono tanti?

Sì, il Mavenclad è uno dei migliori sotto quel profilo.

ma tu non hai avuto più niente da settembre?

(sì, ho dovuto fare tre grammi di cortisone a luglio, non ti dico il casino per trovare un infermiere, e pensa che lavoro pure in ospedale!) No, sto bene.

io non ti voglio chiedere per non disturbarti e innervosirti

(scusa scusa scusa scusa scusa non volevo ammalarmi scusa non è colpa mia ma scusami non pensarci mai più non voglio impensierirti non voglio darti più peso di quello che già porti scusa scusa scusa) Ma chiaramente ci pensi, quindi perché non chiedermelo? Sono contenta se ti posso tranquillizzare.

perché non sei tu a dover tranquillizzare me deve essere il contrario e invece io sono così debole perché non doveva succedere a te potevano toccarmi tutto ma non mia figlia tutti mi dicono che starai bene e tutti dicono cazzate (sì) Sì, mà. Vedremo come andrà.

ma tu stai bene? non hai più sintomi?

(sto benissimo) Sto benissimo!

me lo dici se ti viene qualcosa?

(col cazzo) Certo, mà.

io sto pregando tanto che non ti succeda più niente

(preghi lo stesso dio che mi ha fatta ammalare?) Dai, speriamo che vada tutto bene. (sono fiduciosa) Sono fiduciosa.

tu non sei madre, non puoi capire come mi sento

(hai ragione, hai ragione e ti chiedo scusa per darti ancora questo pensiero) Hai ragione. Ma ho la presunzione di ritenermi l'unica persona che può tranquillizzarti a dovere.

ma io non ti voglio chiedere

Ma l'unico modo per stare tutti tranquilli è farlo.

[thebrokencrescent-blog]

📆 23 Nov 2023 📰 The Relationship Between Epstein-Barr Virus and Multiple Sclerosis ✍️ Bridget A. Bagert 🗞 Neurology Live

In January 2022, Bjornevik and colleagues published the results of a 20-year prospective seroepidemiologic study on the relationship between Epstein-Barr virus (EBV) and multiple sclerosis (MS) in which investigators observed an enormous increase in the risk of MS after EBV infection. They concluded that EBV is the leading cause of MS.

In fact, the idea of an association between EBV and MS is not at all new. The relationship has been suspected for more than 40 years, and evidence therein has been accumulating over the past 2 decades in various fields of medical science, including pathology, epidemiology, immunology, and clinical trials.

In 1980, Sumaya and colleagues were among the first of several groups to report a differential EBV antibody response in patients with MS compared with controls.2 In 2001, Ascherio and colleagues reported on the first prospective seroepidemiologic study addressing this question; the results identified a significantly increased risk of MS after EBV infection.3 Similar prospective seroepidemiologic studies were then conducted in both the United States and Europe in the ensuing decade. In 2013, Pakpoor and colleagues published a meta-analysis of this body of prospective seroepidemiology and concluded that, for an EBV seronegative individual, the odds of developing MS are null.

In 2008, Hauser and colleagues reported the robust and surprising effectiveness of the anti-CD20 drug rituximab (Rituxan; Genentech/Biogen) in a phase 2 trial in relapsing-remitting MS.16 This observation ultimately led to the development and 2017 approval of ocrelizumab (Ocrevus; Genentech), a humanized anti-CD20 agent that has proven to be among the most highly effective disease-modifying therapies for MS available.

The fact that 90% to 95% of the general population have EBV antibodies, yet only a small fraction of them develop MS, adds to the complexity of this story...

... It is established that mononucleosis, a late primary EBV infection that occurs in adolescence, is associated with a higher risk of MS.19-21 Primary EBV infection in infants, by contrast, is usually asymptomatic.22 It is interesting to speculate how a late primary EBV infection may lead to the cascade of immunological events that result in MS. The immune response of adolescents to primary EBV infection is fundamentally different from that of infants. Specifically, in cases of mononucleosis in adolescents, there is a massive expansion of CD8+ T cells in that is not seen in infant infections...

It is also interesting to consider differences in modern hygiene practices that may account for observed differences in the prevalence of primary EBV infection, and whether these changes may influence MS risk. EBV infection is more prevalent in infants than in adolescents in communities with lower socioeconomic status and poor hygiene standards,24,25 and it is well established that the prevalence of MS is lower in countries with lower socioeconomic status than in developed countries. In other words, in countries where primary EBV infection typically occurs in infancy, MS prevalence is lower, and in countries where primary EBV infection commonly occurs in adolescence, MS prevalence is higher, suggesting that the timing of EBV infection may be an important factor in MS risk. Considering that humans have coevolved with EBV over millions of years,26 perhaps the human immune system has evolved in turn to manage EBV more successfully in infancy than in adolescence.

Speculating further on the relationship between the timing of EBV infection and MS risk, the mode of viral transmission may be another key. EBV is transmitted via oral secretions. Throughout human history infants would have been exposed to EBV reliably through the premastication of food passed from mother to child.27-31 The practice of premastication has all but disappeared in modern developed societies, and perhaps with it the opportunity to inoculate young children with EBV at the time in their lives when their immune systems are best able to manage it. Could these relatively recent changes in human hygiene practices explain, in part, the modern increase in the incidence of MS?

[cmr-insights]

Primary Progressive Multiple Sclerosis Treatment Market Size, Share | Global Report 2030

Primary Progressive Multiple Sclerosis (PPMS) is a kind of MS that affects around 15% of all MS patients. PPMS, unlike other types of MS, is distinguished by a progressive worsening of symptoms over time, with no discernible intervals of relapse and remission. This makes it an especially difficult condition to treat, and there are currently no FDA-approved therapies for PPMS.

However, various off-label therapies are utilised to control PPMS symptoms. Corticosteroids, immunosuppressants, and disease-modifying treatments (DMTs) authorised for different types of MS are among them. Physical therapy and rehabilitation are frequently suggested to assist patients in maintaining their mobility and independence.

Make The Smart Decision. Download A Free Sample Of Our Report @ https://cognizancemarketresearch.com/request/primary-progressive-multiple-sclerosis-treatment-market/

The Global Primary Progressive Multiple Sclerosis Treatment Market was valued at US$ 994.3 million in 2022 and is anticipated to reach US$ 3,012.8 million by the end of 2030 expected to register a CAGR of 14.9% from 2023 to 2030.

Several medications targeting PPMS are now under development, including ocrelizumab, Siponimod, and masitinib. The FDA authorised ocrelizumab for the treatment of PPMS in 2017, making it the first medicine specifically approved for this kind of MS. Siponimod and masitinib are currently in clinical studies, but first findings are favourable.

Despite the difficulties associated with treating PPMS, the market for PPMS medicines is projected to expand in the future years as more people are identified and new treatments are discovered. However, the high expense of these medicines may prevent some patients from receiving them, emphasising the need for ongoing research and development of more inexpensive alternatives.

PPMS is a very uncommon variant of MS that affects around 10-15% of all MS patients. It usually appears in people in their 40s or 50s and is more frequent in males than in women. PPMS is distinguished by a progressive worsening of symptoms over time, which might include muscular weakness, trouble walking, tiredness, and visual, speech, and cognition impairments.

Because there are no FDA-approved therapies for PPMS, illness management usually entails a multidisciplinary approach. Medication to treat symptoms, physical therapy and rehabilitation, and assistive technologies to help patients preserve mobility and independence are all possibilities.

As more people are identified and novel therapies are produced, the market for PPMS treatments is projected to rise in the future years. However, the exorbitant expense of these therapies may prevent some patients from receiving them. Furthermore, further study is required to better understand the underlying processes of PPMS and to create more effective and cost-efficient therapies.

https://cognizancemarketresearch.com/wp-content/uploads/2023/09/Primary-Progressive-Multiple-Sclerosis-Treatment-Market.png.webp

Global Primary Progressive Multiple Sclerosis Treatment Market to Amid COVID-19 Pandemic:

The COVID-19 pandemic has had a considerable influence on global healthcare systems, especially the treatment of multiple sclerosis (MS) and its different manifestations, including primary progressive multiple sclerosis (PPMS) (PPMS).

One of the most noticeable consequences of the epidemic has been a disruption in MS patient care, including delays in diagnosis, medication beginning, and routine monitoring. Many clinics and hospitals have decreased or eliminated in-person appointments, favouring telemedicine and remote monitoring. While this has allowed some people to continue getting care, it has also raised access and quality of care concerns. The pandemic has also had an impact on the development and approval of novel PPMS medicines. New medication clinical studies have been postponed.

The pandemic has also had an impact on the development and approval of novel PPMS medicines. Clinical studies for new pharmaceuticals have been delayed or cancelled, and regulatory bodies have struggled to assess and approve novel therapies on time. Furthermore, the pandemic’s economic impact has prompted worries regarding the pricing and accessibility of new medicines for PPMS and other disorders.

Despite these obstacles, there have been some encouraging advancements in the PPMS therapy industry in the midst of the epidemic. The rising use of telemedicine and remote monitoring has emphasised the potential for digital health technology to enhance MS patients’ access and quality of care. Furthermore, the quick development and licencing of COVID-19 vaccines has shown the potential for faster medication development and regulatory processes.

Overall, the COVID-19 pandemic has had a substantial influence on the PPMS treatment industry, presenting patients, healthcare professionals, and pharmaceutical businesses with both problems and possibilities. As the pandemic progresses, it will be critical to monitor its long-term consequences on the PPMS treatment industry and devise measures to limit its bad effects while capitalising on its good ones.

Make The Smart Decision. Download A Free Sample Of Our Report @ https://cognizancemarketresearch.com/request/primary-progressive-multiple-sclerosis-treatment-market/

Emerging Markets for Primary Progressive Multiple Sclerosis Treatment Market:

The rising incidence of the condition in the region, as well as the development of innovative medicines and the use of digital health technology, are driving the emerging market for PPMS treatment in North America. In the United States, for example, it is believed that around 15% of all MS patients have PPMS, with 10,000 new cases identified each year.

In North America, numerous medicines are being developed for the treatment of PPMS, including siponimod and masitinib. Furthermore, the region is home to a number of world-class academic and scientific institutes that are performing cutting-edge research into the disease’s underlying causes and the development of novel therapies.

There is also rising interest in using digital health technologies like telemedicine and remote monitoring to increase access to care for PPMS patients in North America. These technologies have the ability to eliminate barriers to care, such as geographic distance and mobility limitations, while also improving patient outcomes.

Overall, the developing market for PPMS treatment in North America is likely to grow further, owing to a combination of rising illness incidence, breakthroughs in treatment choices, and increased usage of digital health technology.

Competitive Insights:

The market for primary progressive multiple sclerosis (PPMS) therapy is extremely competitive, with numerous established and rising businesses vying for market dominance. Biogen, Novartis, Genzyme, Merck, Teva Pharmaceuticals, and Roche are among the market’s major participants.

[healthkenya7]

PROMISING THERAPIES AND POTENTIAL CURES FOR MULTIPLE SCLEROSIS

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, specifically the brain and spinal cord. It is characterized by the immune system attacking the protective covering of nerve fibers, known as myelin, leading to inflammation, demyelination (loss of myelin), and a range of neurological symptoms. While there is currently no known cure for MS, there are several promising therapies and potential treatments that aim to manage symptoms, slow disease progression, and improve the quality of life for individuals with MS.

Disease-Modifying Therapies (DMTs): These treatments are designed to modify the course of the disease by reducing the frequency and severity of relapses, slowing down disability progression, and delaying the accumulation of new lesions in the brain and spinal cord. There are several classes of DMTs, including interferons, glatiramer acetate, oral immunomodulators, and monoclonal antibodies. Some examples of DMTs include:

Interferons: These are proteins that help regulate the immune system. They can reduce inflammation and the frequency of relapses. Examples include interferon beta-1a and interferon beta-1b.

Glatiramer Acetate: This is a synthetic protein that mimics myelin basic protein, helping to divert the immune system's attack away from the actual myelin.

Oral Immunomodulators: Drugs like fingolimod, siponimod, and teriflunomide modulate immune responses and reduce inflammation. They are taken orally.

Monoclonal Antibodies: Medications like ocrelizumab, alemtuzumab, and natalizumab target specific immune cells or molecules involved in the disease process.

Stem Cell Therapy: Stem cell transplantation involves replacing the immune system with healthy stem cells derived from the patient's own bone marrow or from a donor. This treatment aims to "reset" the immune system and halt the autoimmune attack on myelin. Autologous hematopoietic stem cell transplantation (aHSCT) has shown promising results in clinical trials for aggressive forms of relapsing-remitting MS.

B-cell Depletion: B cells are a type of immune cell that plays a role in the autoimmune response in MS. Monoclonal antibodies targeting CD20-positive B cells, such as ocrelizumab and rituximab, have been shown to reduce relapse rates and disability progression.

Neuroprotection and Remyelination: Some therapies focus on protecting nerve cells and promoting remyelination to repair damaged myelin. These approaches are still in experimental stages but show potential. Drugs like clemastine and opicinumab are being investigated for their ability to enhance remyelination.

Vitamin D Supplementation: There is evidence suggesting that vitamin D deficiency might play a role in MS development and progression. Some studies have shown that maintaining adequate levels of vitamin D through supplementation could have a positive impact on disease activity.

Anti-Inflammatory and Immunosuppressive Therapies: These treatments aim to control the immune response and reduce inflammation. Drugs like corticosteroids are often used to manage acute relapses and reduce inflammation in the central nervous system.

Myelin Repair Therapies: Researchers are exploring strategies to stimulate the repair and regrowth of damaged myelin. This includes promoting the differentiation of oligodendrocyte precursor cells into mature myelin-producing cells.

Personalized Medicine: With advancements in genetics and understanding of individual disease characteristics, personalized treatment plans are becoming more common. Tailoring therapies to the patient's specific disease profile could lead to better outcomes.

Mr. Jayesh Saini notes that, “The effectiveness of these therapies can vary from person to person, and treatment decisions should be made in consultation with a qualified healthcare provider. While significant progress has been made in the field of MS treatment, ongoing research is essential to continue improving therapies and potentially finding a cure in the future.”

#jayeshsaini #healthcare #LifeCareHospitals #Kenya #NHIF #NPS #TSC

[healthwisekenya]

PROMISING THERAPIES AND POTENTIAL CURES FOR MULTIPLE SCLEROSIS

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system,

specifically the brain and spinal cord. It is characterized by the immune system attacking the

protective covering of nerve fibers, known as myelin, leading to inflammation, demyelination

(loss of myelin), and a range of neurological symptoms. While there is currently no known cure

for MS, there are several promising therapies and potential treatments that aim to manage

symptoms, slow disease progression, and improve the quality of life for individuals with MS.

Disease-Modifying Therapies (DMTs): These treatments are designed to modify the course of

the disease by reducing the frequency and severity of relapses, slowing down disability

progression, and delaying the accumulation of new lesions in the brain and spinal cord. There are

several classes of DMTs, including interferons, glatiramer acetate, oral immunomodulators, and

monoclonal antibodies. Some examples of DMTs include:

• Interferons: These are proteins that help regulate the immune system. They can reduce

inflammation and the frequency of relapses. Examples include interferon beta-1a and

interferon beta-1b.

• Glatiramer Acetate: This is a synthetic protein that mimics myelin basic protein, helping

to divert the immune system's attack away from the actual myelin.

• Oral Immunomodulators: Drugs like fingolimod, siponimod, and teriflunomide modulate

immune responses and reduce inflammation. They are taken orally.

• Monoclonal Antibodies: Medications like ocrelizumab, alemtuzumab, and natalizumab

target specific immune cells or molecules involved in the disease process.

Stem Cell Therapy: Stem cell transplantation involves replacing the immune system with healthy

stem cells derived from the patient's own bone marrow or from a donor. This treatment aims to

"reset" the immune system and halt the autoimmune attack on myelin. Autologous

hematopoietic stem cell transplantation (aHSCT) has shown promising results in clinical trials for

aggressive forms of relapsing-remitting MS.

B-cell Depletion: B cells are a type of immune cell that plays a role in the autoimmune response

in MS. Monoclonal antibodies targeting CD20-positive B cells, such as ocrelizumab and rituximab,

have been shown to reduce relapse rates and disability progression.

Neuroprotection and Remyelination: Some therapies focus on protecting nerve cells and

promoting remyelination to repair damaged myelin. These approaches are still in experimental

stages but show potential. Drugs like clemastine and opicinumab are being investigated for their

ability to enhance remyelination.

Vitamin D Supplementation: There is evidence suggesting that vitamin D deficiency might play a

role in MS development and progression. Some studies have shown that maintaining adequate

levels of vitamin D through supplementation could have a positive impact on disease activity.

Anti-Inflammatory and Immunosuppressive Therapies: These treatments aim to control the

immune response and reduce inflammation. Drugs like corticosteroids are often used to manage

acute relapses and reduce inflammation in the central nervous system.

Myelin Repair Therapies: Researchers are exploring strategies to stimulate the repair and

regrowth of damaged myelin. This includes promoting the differentiation of oligodendrocyte

precursor cells into mature myelin-producing cells.

Personalized Medicine: With advancements in genetics and understanding of individual disease

characteristics, personalized treatment plans are becoming more common. Tailoring therapies

to the patient's specific disease profile could lead to better outcomes.

Mr. Jayesh Saini notesthat, “The effectiveness of these therapies can vary from person to person,

and treatment decisions should be made in consultation with a qualified healthcare provider.

While significant progress has been made in the field of MS treatment, ongoing research is

essential to continue improving therapies and potentially finding a cure in the future.”

[screenshots123]

📅 Apr 2021 📰 New links between B cells and EBV infections in women with MS

Recent MS treatments have focused on depleting a type of white blood cell (called B cells), to halt MS relapses and disease progression. These new therapies, such as ocrelizumab (Ocrevus) and ofatumumab (Kesimpta) have directly improved outcomes for people living with MS. These therapies are able to reduce MS relapses by decreasing B cell numbers in the body. Even though we know that B cells are critical to the development of MS, the exact mechanisms by which they do this are not clearly understood.

When a pathogen (such as a virus or bacteria) enters the body, it is “presented” to naïve B cells, which are B cells before they have met an antigen (the pathogen). This stimulates the production of antibodies to defend the individual from the infection. But in MS, where the immune system inappropriately attacks the brain and spinal cord, deposits of antibodies are found in and around areas of damage in the brain. Exactly how these antibodies are produced, their association with B cells, and how they contribute to the damage in the brain in MS is not yet known.

The molecular mechanisms linking EBV and MS are not fully understood; however we do know that EBV chronically infects B cells and causes them to both multiply and be resistant to the natural cell death that would normally occur. B cells are very powerful cells in the immune system and are normally kept under tight control by the body. However, EBV infected B cells might be more resistant to these normal control measures. One theory of how MS develops suggests that if autoimmune B cells (B cells targeting the brain) are infected by EBV, they become resistant to the body’s control systems, and continue to multiply and attack the brain, leading to the development of MS.

Dr Stephanie Trend from The University of Western Australia in Perth, led a research team to investigate B cells, antibodies and signs of EBV infection in the blood. She compared people with MS experiencing a relapse, and people with clinically isolated syndrome (CIS; the first neurological symptoms before a MS diagnosis) to people without MS or “healthy controls”.

In particular, the research team measured levels of a receptor molecule on the surface of B cells called CD32b. Receptor CD32b senses the presence of antibodies, prompting the B cells to reduce their response. It is thought that this acts as a feedback loop to stop B cells from responding excessively after an immune response has been successfully established. In laboratory models, CD32b is also important in shutting down autoimmune responses, preventing B cells from targeting the individual.

The research revealed, for the first time, that levels of CD32b are lower on particular types of B cells in people with MS and CIS when compared to healthy controls, but this was only in women. Thus, it is possible that B cells in women with MS are less able to switch off excessive responses, and/or less able to switch off autoimmune responses.

The team also found that this phenomenon in women with MS was associated with higher levels of a special B cell activating factor in the blood, with tests suggesting that the previously inactive EBV in the body was reactivated. This was particularly evident in the people with CIS. This points to a possible relationship between these particular B cells and control of an EBV infection in women with MS. These new discoveries were recently published in the prestigious journal (Frontiers in Immunology).

[sclerosismultiplex]

Kwalifikacje do leczenia okrelizumabem (Ocrevus)

[currentsinbiology]

New Multiple Sclerosis Drug, Backed by 40 Years of Research, Could Halt Disease

A newly approved drug that is the first to reflect the current scientific understanding of multiple sclerosis (MS) – is holding new hope for the hundreds of thousands Americans living with the disease.

It also highlights the importance of clinician-scientists like UC San Francisco’s Stephen Hauser, MD, who are working to transform research into cures for patients.

The Food and Drug Administration on Tuesday approved ocrelizumab (brand name Ocrevus) to treat both relapsing-remitting MS and primary progressive MS, the first time a therapy has been available for severe forms of the disease.

The drug, the first that targets B cells in the human body, grew out of the work of Hauser, chair of neurology at UCSF, whose team persevered for decades in elucidating the science behind MS, defending findings that contradicted long-standing assumptions and translating the science into a therapy.

An MRI scan of a person with multiple sclerosis shows bright spots, which are MS plaques. NeuroscienceNews.com image is credited to NIH.

[merlinhoot]

[u2hearts]

Ocrevus, Rituxan not new drugs

Ocrevus, Rituxan not new drugs

I received an email yesterday about a new drug for progressive MS called Ocrevus. https://www.cbsnews.com/video/new-drug-provides-hope-for-those-suffering-with-ms/I don’t get it, I’ve been on Ocrevus for almost 2 years already. Is it really still new news?

I wish I could rave about this drug that it has done wonders for me, but it hasn’t. I haven’t had any relapses and for that I am thankful but…

[neurocirurgiabr]

In MS, Serious AEs More Common in Rituximab vs Ocrelizumab

http://dlvr.it/RgRDGB

[sciencethot]

To my friends, I know that this day is one great tribute. But to me and my family today is one has a lot more meaning for us. September 11th 2001 is the day that the most wonderful, caring, open, and hard headed person I know, my mom, was diagnosed with Multiple Sclerosis. Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system, which is made up of the brain, spinal cord, and optic nerves. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. The progress, severity, and specific symptoms of MS are unpredictable and vary from one person to another. After being in the hospital for almost a week and being treated for everything from a stroke to heart issues the doctor finally figured out what the issue was. The plus to this story is that if her health hadn’t taken a severe down turn, my dad would have been in Manhattan for a job interview at the same time. It seems like a tradeoff. My dad believes he would of been there. So yes, I still have both parents but I have to watch as one slowly dies and I can do nothing about it.

As an update, the doctors have recommended a change to my mom's medication. She's has been on Gilenya for about 7 years. Gilenya is a daily medication that (simplified) works by cutting down the white blood cells. The issue with this is that it allows her to get sick very easily.

The neurologist has recommended a change to OCREVUS® (ocrelizumab). This is a medication that is done as a infusion that is done two times a year. The medicine has shown to be leaps and bounds above the previous medicines. Her first infusion is scheduled for October 8th.

[ultimavoce]

Sclerosi multipla: il nuovo farmaco somministrato su tre pazienti

Nuovi risultati per la #sclerosimultipla: il nuovo farmaco è stato testato su tre pazienti.

Ospedale Sant’Elia di Caltanissetta – Risale a qualche giorno fa il primo utilizzo dello Ocrelizumab; il nuovo farmaco è quasi in concomitanza con la giornata mondiale della sclerosi multipla.

Il farmaco è idoneo a forme primariamente progressive e secondariamente progressive, sino ad oggi intrattabili con farmaci specifici. Michele Vecchio, primario dell’ospedale di Sant’Elia e presidente…

[meistrworld]

Give people with PPMS the treatment they need, MS Society campaign #SpeakupforMS

Give people with PPMS the treatment they need, MS Society campaign #SpeakupforMS

Blocking of a drug as a treatment for primary progressive multiple sclerosis (PPMS), making it unavailable for use by the UK’s National Health Service (NHS), is being challenged by the country’s MS Society.

And it has coupled its opposition with a call to arms – inviting everyone to #SpeakupforMS.

Holly (Pic: MS Society).

Holly, from the society’s campaigns community, lives with PPMS. She says:…